White Paper | 2021 Annual Meeting | Assessing the Use of ctDNA as an Early Endpoint in Early-Stage Disease | February 3, 2022 Share
White Paper | 2021 Annual Meeting | Optimizing Dosing in Oncology Drug Development | February 3, 2022 Share
White Paper | 2018 Annual Meeting | Exploring the Use of Circulating Tumor DNA as a Monitoring Tool for Drug Development | November 24, 2020 Share
White Paper | 2018 Annual Meeting | Real-Time Oncology Review and the Assessment Aid | November 24, 2020 Share
White Paper | 2018 Annual Meeting | Exploring Whether a Synthetic Control Arm Can Be Derived from Historical Clinical Trials that Match Baseline Characteristics and Overall Survival Outcome of a Randomized Control Arm | November 24, 2020 Share
White Paper | 2020 Annual Meeting: Optimizing the Use of Accelerated Approval | November 13, 2020 Share
White Paper | Annual Meeting 2020 | Modernizing Expedited Development Programs | November 13, 2020 Share
White Paper | 2019 Annual Meeting | Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products | November 13, 2019 Share
White Paper | 2019 Annual Meeting | Immuno-Oncology Combination Drug Development for Patients with Disease Progression After Initial anti-PD-(L)1 Therapy | November 13, 2019 Share
White Paper | 2019 Annual Meeting | Characterizing the Use of External Controls for Augmenting Randomized Control Arms and Confirming Benefit | November 8, 2019 Share
